These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38764445)

  • 1. Real-world non-interventional post-authorization safety study of long-term use of burosumab in children and adolescents with X-linked hypophosphatemia: first interim analysis.
    M Boot A; Ariceta G; Beck-Nielsen SS; Brandi ML; Briot K; Collantes CL; Giannini S; Haffner D; Keen R; Levtchenko E; Mughal MZ; Makitie O; Nilsson O; Schnabel D; Tripto-Shkolnik L; Zillikens MC; Liu J; Tudor A; Emma F
    Ther Adv Chronic Dis; 2024; 15():20406223241247643. PubMed ID: 38764445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-linked hypophosphataemia: rationale and description.
    Brandi ML; Ariceta G; Beck-Nielsen SS; Boot AM; Briot K; de Lucas Collantes C; Emma F; Giannini S; Haffner D; Keen R; Levtchenko E; Mӓkitie O; Nilsson O; Schnabel D; Tripto-Shkolnik L; Zillikens MC; Liu J; Tudor A; Mughal MZ
    Ther Adv Chronic Dis; 2022; 13():20406223221117471. PubMed ID: 36082134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What are the benefits of the anti-FGF23 antibody burosumab on the manifestations of X-linked hypophosphatemia in adults in comparison with conventional therapy? A review.
    Lafage-Proust MH
    Ther Adv Rare Dis; 2022; 3():26330040221074702. PubMed ID: 37180412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
    Insogna KL; Briot K; Imel EA; Kamenický P; Ruppe MD; Portale AA; Weber T; Pitukcheewanont P; Cheong HI; Jan de Beur S; Imanishi Y; Ito N; Lachmann RH; Tanaka H; Perwad F; Zhang L; Chen CY; Theodore-Oklota C; Mealiffe M; San Martin J; Carpenter TO;
    J Bone Miner Res; 2018 Aug; 33(8):1383-1393. PubMed ID: 29947083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia.
    Linglart A; Imel EA; Whyte MP; Portale AA; Högler W; Boot AM; Padidela R; Van't Hoff W; Gottesman GS; Chen A; Skrinar A; Scott Roberts M; Carpenter TO
    J Clin Endocrinol Metab; 2022 Feb; 107(3):813-824. PubMed ID: 34636899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Burosumab Treatment on Mineral Metabolism in Children and Adolescents With X-linked Hypophosphatemia.
    Ewert A; Rehberg M; Schlingmann KP; Hiort O; John-Kroegel U; Metzing O; Wühl E; Schaefer F; Kemper MJ; Derichs U; Richter-Unruh A; Patzer L; Albers N; Dunstheimer D; Haberland H; Heger S; Schröder C; Jorch N; Schmid E; Staude H; Weitz M; Freiberg C; Leifheit-Nestler M; Zivicnjak M; Schnabel D; Haffner D
    J Clin Endocrinol Metab; 2023 Sep; 108(10):e998-e1006. PubMed ID: 37097907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-in-Asian Phase I Study of the Anti-Fibroblast Growth Factor 23 Monoclonal Antibody, Burosumab: Safety and Pharmacodynamics in Adults With X-linked Hypophosphatemia.
    Cheong HI; Yoo HW; Adachi M; Tanaka H; Fujiwara I; Hasegawa Y; Harada D; Sugimoto M; Okada Y; Kato M; Shimazaki R; Ozono K; Seino Y
    JBMR Plus; 2019 Feb; 3(2):e10074. PubMed ID: 30828689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Burosumab treatment of X-linked hypophosphatemia patients: interim analysis of the SUNFLOWER longitudinal, observational cohort study.
    Michigami T; Kang HG; Namba N; Ito N; Kubota T; Shintani A; Kabata D; Kanematsu M; Nishida Y; Fukumoto S; Ozono K
    JBMR Plus; 2024 Aug; 8(8):ziae079. PubMed ID: 39015507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia.
    Imanishi Y; Ito N; Rhee Y; Takeuchi Y; Shin CS; Takahashi Y; Onuma H; Kojima M; Kanematsu M; Kanda H; Seino Y; Fukumoto S
    J Bone Miner Res; 2021 Feb; 36(2):262-270. PubMed ID: 32967046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth pattern in children with X-linked hypophosphatemia treated with burosumab and growth hormone.
    Ertl DA; Le Lorier J; Gleiss A; Trabado S; Bensignor C; Audrain C; Zhukouskaya V; Coutant R; Berkenou J; Rothenbuhler A; Haeusler G; Linglart A
    Orphanet J Rare Dis; 2022 Nov; 17(1):412. PubMed ID: 36371259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Burosumab and Dental Abscesses in Children With X-Linked Hypophosphatemia.
    Gadion M; Hervé A; Herrou J; Rothenbuhler A; Smail-Faugeron V; Courson F; Linglart A; Chaussain C; Biosse Duplan M
    JBMR Plus; 2022 Nov; 6(11):e10672. PubMed ID: 36398111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticipated effects of burosumab treatment on long-term clinical sequelae in XLH: expert perspectives.
    Seefried L; Duplan MB; Briot K; Collins MT; Evans R; Florenzano P; Hawkins N; Javaid MK; Lachmann R; Ward LM
    Front Endocrinol (Lausanne); 2023; 14():1211426. PubMed ID: 37547321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia.
    Weber TJ; Imel EA; Carpenter TO; Peacock M; Portale AA; Hetzer J; Merritt JL; Insogna K
    J Clin Endocrinol Metab; 2022 Dec; 108(1):155-165. PubMed ID: 36072994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. X-linked hypophosphatemic rickets and nephrocalcinosis: clinical characteristics of a single-center pediatric cohort in North America before and after burosumab.
    Paloian NJ; Boyke-Lohmann LR; Steiner RD
    Front Pediatr; 2024; 12():1430921. PubMed ID: 39156019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. X-linked hypophosphatemia and burosumab: Practical clinical points from the French experience.
    Bacchetta J; Rothenbuhler A; Gueorguieva I; Kamenicky P; Salles JP; Briot K; Linglart A
    Joint Bone Spine; 2021 Oct; 88(5):105208. PubMed ID: 34102329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent Lower Limb Deformities Despite Amelioration of Rickets in X-Linked Hypophosphatemia (XLH) - A Prospective Observational Study.
    Mindler GT; Stauffer A; Kranzl A; Penzkofer S; Ganger R; Radler C; Haeusler G; Raimann A
    Front Endocrinol (Lausanne); 2022; 13():866170. PubMed ID: 35399930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period.
    Portale AA; Carpenter TO; Brandi ML; Briot K; Cheong HI; Cohen-Solal M; Crowley R; Jan De Beur S; Eastell R; Imanishi Y; Imel EA; Ing S; Ito N; Javaid M; Kamenicky P; Keen R; Kubota T; Lachmann R; Perwad F; Pitukcheewanont P; Ralston SH; Takeuchi Y; Tanaka H; Weber TJ; Yoo HW; Zhang L; Theodore-Oklota C; Mealiffe M; San Martin J; Insogna K
    Calcif Tissue Int; 2019 Sep; 105(3):271-284. PubMed ID: 31165191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. X-Linked Hypophosphatemia: A New Era in Management.
    Dahir K; Roberts MS; Krolczyk S; Simmons JH
    J Endocr Soc; 2020 Dec; 4(12):bvaa151. PubMed ID: 33204932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia.
    Ward LM; Glorieux FH; Whyte MP; Munns CF; Portale AA; Högler W; Simmons JH; Gottesman GS; Padidela R; Namba N; Cheong HI; Nilsson O; Mao M; Chen A; Skrinar A; Roberts MS; Imel EA
    J Clin Endocrinol Metab; 2022 Jul; 107(8):e3241-e3253. PubMed ID: 35533340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-Administration of Burosumab in Children and Adults with X-Linked Hypophosphataemia in Two Open-Label, Single-Arm Clinical Studies.
    Kubota T; Namba N; Tanaka H; Muroya K; Imanishi Y; Takeuchi Y; Kanematsu M; Sun W; Seino Y; Ozono K
    Adv Ther; 2023 Apr; 40(4):1530-1545. PubMed ID: 36719566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.